Cited by 304Nicotinic Acetylcholine Receptors StudyCholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

The DOI matches its Crossref record; 77 of the 80 references it cites were found in a registry or an index.

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

Maelicke, Alfred, Samochocki, Marek, Jostock, Ruth, Fehrenbacher, Andreas, Ludwig, Jürgen, Albuquerque, Edson X, Zerlin, Marion·2001·Biological Psychiatry

DOI 10.1016/s0006-3223(00)01109-4

Open this paper in CoChat — free account

Abstract

Cholinesterase inhibitors are the only approved drug treatment for patients with mild to moderately severe Alzheimer's disease. Interestingly, the clinical potency of these drugs does not correlate well with their activity as cholinesterase inhibitors, nor is their action as short lived as would be expected from purely symptomatic treatment. A few cholinesterase inhibitors, including galantamine, produce beneficial effects even after drug treatment has been terminated. These effects assume modes of action other than mere esterase inhibition and are capable of inducing systemic changes. We have recently discovered a mechanism that could account, at least in part, for the above-mentioned unexpected properties of some cholinesterase inhibitors. We have found that a subgroup of cholinesterase inhibitors, including galantamine but excluding tacrine, directly interacts with nicotinic acetylcholine receptors. These compounds, named allosterically potentiating ligands, sensitize nicotinic receptors by increasing the probability of channel opening induced by acetylcholine and nicotinic agonists and by slowing down receptor desensitization. The allosterically potentiating ligand action, which is not necessarily associated with cholinesterase inhibition, has been demonstrated by whole-cell patch-clamp recordings to occur in natural murine and human neurons and in murine and human cell lines expressing various subtypes of neuronal nicotinic acetylcholine receptors.

Integrity signals

Registry

Crossref · 10.1016/s0006-3223(00)01109-4

Cites

77 of 78 references verified0 citation errors · 1 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy
Steinlein, O. K., Mulley, J. C., Propping, P., Wallace, R. H., Phillips, H. A., Sutherland, G. R., Scheffer, I. E., & Berkovic, S. F. (1995) · Nature Genetics · doi:10.1038/ng1095-201 · Cited by 1,134
β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D’Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 818
Handbook of Experimental Pharmacology, vol 14.
Freedman, A. D. (1972) · Archives of Internal Medicine · doi:10.1001/archinte.1972.03650020118031 · Cited by 777
Pharmacology of Nicotine: Addiction and Therapeutics
Benowitz, N. L. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.003121 · Cited by 589
Acute stress facilitates long-lasting changes in cholinergic gene expression
Kaufer, D., Friedman, A., Seidman, S., & Soreq, H. (1998) · Nature · doi:10.1038/30741 · Cited by 588
Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment
Marks, M., Pauly, Jr., Gross, S., Deneris, E., Hermans-Borgmeyer, I., Heinemann, S., & Collins, A. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02765.1992 · Cited by 551
Basal forebrain neurons in the dementia of Parkinson disease
Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. (1983) · Annals of Neurology · doi:10.1002/ana.410130304 · Cited by 535

Show all 80 references

Research works printed but not linked: 5

Inestrosa NC, De Ferrari GV (2000): Acetylcholinesterase-induced β-amyloid aggregation and neurotoxicity. In: Sixth Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Abstract 87.
Lahiri DK, Farlow MR, Ge Y, Utsuki T, Greig NH (2000): Regulation of βAPP processing with cholinesterase inhibitors in neuronal cell lines. In: Sixth Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Abstract 96.
Pereira, 1994, Physostigmine and galantamine, J Pharmacol Exp Ther, 270, 768
Perry, 1999, Increased nicotinic receptors in brains from smokers, J Pharmacol Exp Ther, 289, 1545
Soreq H, Sternfeld M, Flores-Flores C, Salmon A, Ginzberg D, Seidman S (2000): Multifaced role of acetylcholinesterase in Alzheimer’s disease. In: Sixth Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Abstract 146.

Sorted by citations

Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Nicotinic acetylcholine receptors: from structure to brain function
Hogg, R. C., Raggenbass, M., & Bertrand, D. (2003) · Springer eBooks · doi:10.1007/s10254-003-0005-1 · Cited by 536
Nicotinic ACh receptors as therapeutic targets in CNS disorders
Dineley, K. T., Pandya, A. A., & Yakel, J. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.002 · Cited by 460
Amaryllidaceae and Sceletium alkaloids
Jin, Z. (2013) · Natural Product Reports · doi:10.1039/c3np70005d · Cited by 409
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts
López, S., Bastida, J., Viladomat, F., & Codina, C. J. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02034-9 · Cited by 359
Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors
Samochocki, M., Höffle‐Maas, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin, M., Ullmer, C., Pereira, E. F. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045773 · Cited by 345
Self-citation
Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease
Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309
Synthesis and Pharmacology of Galantamine
Marco, J. L., Carreiras, M. C., Rodríguez, C., Villarroya, M., & Garcı́a, A. G. (2005) · Chemical Reviews · doi:10.1021/cr040415t · Cited by 296
Pharmacologic treatments of dementia
Bonner, L. T., & Peskind, E. R. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00007-x · Cited by 226
Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons
Takada, Y., Yonezawa, A., Kume, T., Katsuki, H., Kaneko, S., Sugimoto, H., & Akaike, A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050104 · Cited by 209
Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of α4 and α7 Receptors in Neuroprotection
Akaike, A., Takada‐Takatori, Y., Kume, T., & Izumi, Y. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9236-1 · Cited by 200
Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders
Sacco, K. A., Bannon, K. L., & George, T. P. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104047273 · Cited by 203
Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors
McKay, B. E., Placzek, A. N., & Dani, J. A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.001 · Cited by 181
Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors
Takata, K., Kitamura, Y., Saeki, M., Terada, M., Kagitani, S., Kitamura, R., Fujikawa, Y., Maelicke, A., Tomimoto, H., Taniguchi, T., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.142356 · Cited by 176
Self-citation
Dementia of the Alzheimer Type
Jalbert, J. J., Daiello, L. A., & Lapane, K. L. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn008 · Cited by 181
Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability
Fowler, C. D., & Kenny, P. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.008 · Cited by 176
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia
Friedman, J. I., Adler, D. N., Howanitz, E. M., Harvey, P. D., Brenner, G. H., Temporini, H. D., WHITE, L. E., & Parrella, M. J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01342-7 · Cited by 168
Cholinesterase inhibitors in the treatment of dementia.
Ellis, J. M. (2005) · PubMed · Cited by 161
Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms
Mudó, G., Belluardo, N., & Fuxe, K. (2006) · Journal of neural transmission · doi:10.1007/s00702-006-0561-z · Cited by 125
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
Darreh‐Shori, T., Almkvist, O., Guan, Z. Z., Garlind, A., Strandberg, B., Svensson, A., Soreq, H., Hellström‐Lindahl, E., & Nordberg, A. K. (2002) · Neurology · doi:10.1212/wnl.59.4.563 · Cited by 154
Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
Bhattacharya, S., Haertel, C., Maelicke, A., & Montag, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089454 · Cited by 142
“Whereas donepezil and rivastigmine are designed acetylcholinesterase inhibitors, the plant alkaloid galantamine additionally acts as an allosterically potentiating ligand of nicotinic receptors, increasing their sensitivity to the neurotransmitter acetylcholine [9].”
Self-citation
Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone
Schubert, M., Young, K. A., & Hicks, P. B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.006 · Cited by 140
Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations
Misra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136
Clinical Pharmacokinetics of Galantamine
Farlow, M. R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00005 · Cited by 134
Galantamine Enhances Dopaminergic Neurotransmission In Vivo Via Allosteric Potentiation of Nicotinic Acetylcholine Receptors
Schilström, B., Ivanov, V., Wiker, C., & Svensson, T. H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301087 · Cited by 128
Nicotinic Acetylcholine Receptors at Glutamate Synapses Facilitate Long-Term Depression or Potentiation
Ge, S., & Dani, J. A. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0542-05.2005 · Cited by 132
Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity
Kihara, T., Sawada, H., Nakamizo, T., Kanki, R., Yamashita, H., Maelicke, A., & Shimohama, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.132 · Cited by 124
Self-citation
Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release
Zhang, L., Zhou, F.-M., & Dani, J. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.000299 · Cited by 122
Does kynurenic acid act on nicotinic receptors? An assessment of the evidence
Stone, T. W. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14907 · Cited by 123
Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine
Ago, Y., Koda, K., Takuma, K., & Matsuda, T. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r01cr · Cited by 118
Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications
Romanelli, M. N., & Gualtieri, F. (2003) · Medicinal Research Reviews · doi:10.1002/med.10037 · Cited by 112
Stimulating Nicotinic Receptors Trigger Multiple Pathways Attenuating Cytotoxicity in Models of Alzheimer's and Parkinson's Diseases
Kawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111
β-Amyloid Directly Inhibits Human α4β2-Nicotinic Acetylcholine Receptors Heterologously Expressed in Human SH-EP1 Cells
Wu, J., Kuo, Y., George, A. A., Xu, L., Hu, J., & Lukas, R. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400335200 · Cited by 112
Galantamine for Alzheimer's disease
Prvulovic, D., Hampel, H. J., & Pantel, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003592137 · Cited by 113
Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimers Disease: A Review of Recent Clinical Studies
Darreh‐Shori, T., & Soininen, H. S. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274455 · Cited by 106
Nicotinic receptors and schizophrenia
Ripoll, N., Grall‐Bronnec, M., & Bourin, M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004060 · Cited by 106
Plant Sources of Galanthamine: Phytochemical and Biotechnological Aspects
Berkov, S. H., Georgieva, L., Kondakova, V., Atanassov, A. I., Viladomat, F., Bastida, J., & Codina, C. J. (2009) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2009.10817633 · Cited by 105
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD
Kadir, A., Darreh‐Shori, T., Almkvist, O., Wall, A., Grut, M., Strandberg, B., Ringheim, A., Eriksson, B., Blomquist, G., Långström, B., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.020 · Cited by 103
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Cholinergic imaging in dementia spectrum disorders
Roy, R., Niccolini, F., Pagano, G., & Politis, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3349-x · Cited by 101
Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S., Chougule, M. B., Shoyele, S., Gupta, U. D., Ajazuddin, M., et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 101
Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders
Sacco, K. A., Bannon, K. L., & George, T. P. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800403 · Cited by 100
Antioxidant, anti-diabetic, acetylcholinesterase inhibitory potential and estimation of alkaloids (lycorine and galanthamine) from Crinum species: An important source of anticancer and anti-Alzheimer drug
Ghane, S. G., Attar, U. A., Yadav, P. B., & Lekhak, M. M. (2018) · Industrial Crops and Products · doi:10.1016/j.indcrop.2018.08.087 · Cited by 99
Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.
Rezvani, A., Kholdebarin, E., Brucato, F., Callahan, P., Lowe, D., & Levin, E. (2009) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.018 · Cited by 97
Disease-Modifying Therapies in Alzheimer???s Disease
ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 95
Clinically Significant Drug Interactions with Cholinesterase Inhibitors
Bentu??-Ferrer, D., Tribut, O., Polard, É., & Allain, H. (2003) · CNS Drugs · doi:10.2165/00023210-200317130-00002 · Cited by 92
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease
Echeverría, V., Iarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 95
AProspective, Open-Label Trial of Galantamine in Autistic Disorder
Nicolson, R., Craven‐Thuss, B., & Smith, J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.621 · Cited by 90
Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer's disease
Disterhoft, J. F., Wu, W., & Ohno, M. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2004.07.001 · Cited by 90
Cholinergic systems in progressive supranuclear palsy
Warren, N. (2004) · Brain · doi:10.1093/brain/awh391 · Cited by 91
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years
Bullock, R. M., & Dengiz, A. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00562.x · Cited by 87
Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial
Ghaleiha, A., Ghyasvand, M., Mohammadi, M.-R., Farokhnia, M., Yadegari, N., Tabrizi, M. H., Hajiaghaee, R., Yekehtaz, H., & Akhondzadeh, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113508830 · Cited by 90
Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome
Cubells, J. F., DeOreo, E. H., Harvey, P. D., Garlow, S. J., Garber, K. B., Adam, M. P., & Martin, C. L. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33917 · Cited by 87
Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease
Panza, F., Solfrizzi, V., Frisardi, V., Capurso, C. A., D’Introno, A., Colacicco, A. M., Vendemiale, G., Capurso, A., & Imbimbo, B. P. (2009) · Drugs & Aging · doi:10.2165/11315770-000000000-00000 · Cited by 87
Modulation of α7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-β Interactions in Alzheimer's Disease Brain
Ni, R., Marutle, A., & Nordberg, A. K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121447 · Cited by 84
REVIEW: γ‐Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State
Panza, F., Frisardi, V., Imbimbo, B. P., Capurso, C. A., Logroscino, G., Sancarlo, D., Seripa, D., Vendemiale, G., Pilotto, A., & Solfrizzi, V. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00164.x · Cited by 80
An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia
Erkinjuntti, T., Kurz, A., Small, G. W., Bullock, R. A., Lilienfeld, S., & Damaraju, C. V. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80168-6 · Cited by 79
Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways
Wazea, S. A., Wadie, W., Bahgat, A. K., & El-Abhar, H. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23359-6 · Cited by 79
Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH‐SY5Y neuroblastoma cells
Romero, A., Egea, J., Garcı́a, A. G., & López, M. G. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00778.x · Cited by 79
An update on the pharmacology of galantamine
Villarroya, M., Garcı́a, A. G., Marco, J. L., & López, M. G. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1987 · Cited by 79
Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation
SHARMA, T., REED, C., Aasen, I., & Kumari, V. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.037 · Cited by 79
Development and validation of a GC–MS method for rapid determination of galanthamine in Leucojum aestivum and Narcissus ssp.: A metabolomic approach
Berkov, S. H., Bastida, J., Viladomat, F., & Codina, C. J. (2010) · Talanta · doi:10.1016/j.talanta.2010.11.029 · Cited by 78
Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study
Shearman, E., Rossi, S., Szász, B. K., Jurányi, Z., Fallon, S. M., Pomara, N., Sershen, H. W., & Lajtha, Á. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.12.001 · Cited by 77
N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum
Berkov, S. H., Codina, C. J., Viladomat, F., & Bastida, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.008 · Cited by 78
Current and Emerging Pharmacological Treatment Options for Dementia
Ringman, J. M., & Cummings, J. L. (2006) · Behavioural Neurology · doi:10.1155/2006/315386 · Cited by 77
Galantamine promotes adult hippocampal neurogenesis via M1 muscarinic and α7 nicotinic receptors in mice
Kita, Y., Ago, Y., Higashino, K., Asada, K., Takano, E., Takuma, K., & Matsuda, T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000613 · Cited by 75
Rapid TLC/GC‐MS identification of acetylcholinesterase inhibitors in alkaloid extracts
Berkov, S. H., Bastida, J., Nikolova, M. T., Viladomat, F., & Codina, C. J. (2008) · Phytochemical Analysis · doi:10.1002/pca.1066 · Cited by 74
Alcohol use and the risk of developing Alzheimer's disease.
Tyas, S. L. (2001) · PubMed Central · Cited by 65
Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats
Hohnadel, E. J., Bouchard, K., & Terry, A. V. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.025 · Cited by 65
Antioxidant Activity of Galantamine and Some of its Derivatives
Tsvetkova, D. D., Obreshkova, D. P., Zheleva‐Dimitrova, D., & Saso, L. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990148 · Cited by 65
Pharmacological and molecular enhancement of learning in aging and Alzheimer’s disease
Disterhoft, J. F., & Oh, M. M. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2005.12.079 · Cited by 64
Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking
Ochoa, E. L. M., & Lasalde‐Dominicci, J. A. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9149-x · Cited by 64
The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease
Grantham, C., & Geerts, H. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00274-5 · Cited by 64
Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET
Kadir, A., Darreh‐Shori, T., Almkvist, O., Wall, A. E., Långström, B., & Nordberg, A. K. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0725-z · Cited by 63
The effects of galantamine treatment on caregiver time in Alzheimer's disease
Sano, M., Wilcock, G. K., van Baelen, B., & Kavanagh, S. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1000 · Cited by 62
Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp
Nukoolkarn, V. S., Saen‐oon, S., Rungrotmongkol, T., Hannongbua, S. V., Ingkaninan, K., & Suwanborirux, K. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.027 · Cited by 61
Increased Sensitivity to Agonist-Induced Seizures, Straub Tail, and Hippocampal Theta Rhythm in Knock-In Mice Carrying Hypersensitive α4 Nicotinic Receptors
Fonck, C., Nashmi, R., Deshpande, P., Damaj, M. I., Marks, M. J., Riedel, A., Schwarz, J., Collins, A. C., Labarca, C. G., & Lester, H. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02582.2003 · Cited by 69
Metabolic profiling of bioactive Pancratium canariense extracts by GC‐MS
Torras‐Claveria, L., Berkov, S. H., Jáuregui, O., Caujapé, J., Viladomat, F., Codina, C. J., & Bastida, J. (2009) · Phytochemical Analysis · doi:10.1002/pca.1158 · Cited by 61
Alkaloid Constituents of the Amaryllidaceae Plant Amaryllis belladonna L
Tallini, L. R., de Andrade, J. P., Kaiser, M., Viladomat, F., Nair, J. J., Zuanazzi, J. Â. S., & Bastida, J. (2017) · Molecules · doi:10.3390/molecules22091437 · Cited by 59
Nicotinic Acetylcholine Receptor Signaling in Neuroprotection
Akaike, A., Shimohama, S., & Misu, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1 · Cited by 61
The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease
Sabbagh, M. N., Lukas, R. J., Sparks, D. L., & Reid, R. T. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4407 · Cited by 57
Mechanism of Action of Galantamine on N-Methyl-d-Aspartate Receptors in Rat Cortical Neurons
Moriguchi, S., Marszalec, W., Zhao, X., Yeh, J. Z., & Narahashi, T. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067603 · Cited by 57
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats
Nikiforuk, A., Kos, T., Hołuj, M., Potasiewicz, A., & Popik, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.034 · Cited by 55
GALANTAMINE: A REVIEW OF ITS USE IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA
Corey, J. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10467.x · Cited by 55
Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease
Kurz, A., Erkinjuntti, T., Small, G. W., Lilienfeld, S., & Damaraju, C. V. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00677.x · Cited by 54
Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.
Takada‐Takatori, Y., Kume, T., Izumi, Y., Ohgi, Y., Niidome, T., Fujii, T., Sugimoto, H., & Akaike, A. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.318 · Cited by 59
Chronic Cerebral Hypoperfusion Accelerates Alzheimer’s Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model
Zhai, Y., Yamashita, T., Nakano, Y., Sun, Z., Shang, J., Feng, T., Morihara, R., Fukui, Y., Ohta, Y., Hishikawa, N., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160345 · Cited by 55
Diastereoselective Total Synthesis of (±)‐Codeine
Varin, M., Barré, E., Iorga, B. I., & Guillou, C. (2008) · Chemistry - A European Journal · doi:10.1002/chem.200800744 · Cited by 53
Galantamine in the Treatment of Adult Autism: A Report of Three Clinical Cases
Hertzman, M. (2003) · The International Journal of Psychiatry in Medicine · doi:10.2190/je5q-1nft-fl40-7pmw · Cited by 53
Daffodils as potential crops of galanthamine. Assessment of more than 100 ornamental varieties for their alkaloid content and acetylcholinesterase inhibitory activity
Torras‐Claveria, L., Berkov, S. H., Codina, C. J., Viladomat, F., & Bastida, J. (2012) · Industrial Crops and Products · doi:10.1016/j.indcrop.2012.07.034 · Cited by 51
Cholinesterase Inhibition Activity, Alkaloid Profiling and Molecular Docking of Chilean Rhodophiala (Amaryllidaceae)
Tallini, L. R., Bastida, J., Cortés, N., Osorio, E. H., Theoduloz, C., & Schmeda‐Hirschmann, G. (2018) · Molecules · doi:10.3390/molecules23071532 · Cited by 51
Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind fMRI study
Kumari, V., Aasen, I., Ffytche, D. H., Williams, S., & Sharma, T. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.08.013 · Cited by 50
The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors
Nikiforuk, A., Potasiewicz, A., Kos, T., & Popik, P. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.023 · Cited by 53
Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein
Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B. P., Capurso, C. A., D’Introno, A., Colacicco, A. M., Seripa, D., Vendemiale, G., Capurso, A., et al. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03327445 · Cited by 49
Effect of galantamine on the human α7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity
Texidó, L., Ros, E., Martı́n-Satué, M., López, S., Aleu, J., Marsal, J., & Solsona, C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706221 · Cited by 47

Authors: Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M.
Affiliations: Johannes Gutenberg University Mainz (DE)
Corresponding author: Maelicke, Alfred
ORCID: Jostock, Ruth
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2001-02
Volume: 49
Issue: 3
Pages: 279-288
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/s0006-3223(00)01109-4
OpenAlex: W2043467860
Cited by: 303
References: 80
Citations by year: 2026: 7 · 2025: 3 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 9 · 2020: 17 · 2019: 10 · 2018: 13 · 2017: 6 · 2016: 11 · 2015: 11 · 2014: 6 · 2013: 11 · 2012: 9
FWCI: 1.65
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: galantamine, nicotinic acetylcholine receptors, Alzheimer's disease, cholinesterase inhibitors, tacrine, receptor desensitization, acetylcholine, off-target effects
MeSH terms: Allosteric Regulation, Allosteric Site, Alzheimer Disease, Animals, Cell Line, Cholinesterase Inhibitors, Galantamine, Humans, Neurons, Receptors, Nicotinic, Patch-Clamp Techniques, Nootropic Agents, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks